

National Institute for Health and Clinical Excellence

Single Health Technology Appraisal (STA)

Trastuzumab for the treatment of HER-2 positive advanced gastric cancer

Response to consultee and commentator comments on the draft remit and draft scope (pre-referral)

Comment 1: the draft remit

Section	Consultees	Comments	Action
Appropriateness	N/A	No comments received	No actions required
Wording	N/A	No comments received	No actions required
Timing Issues	N/A	No comments received	No actions required
Additional comments on the draft remit	N/A	No comments received	No actions required

Comment 2: the draft scope

Section	Consultees	Comments	Action
Background information	N/A	No comments received	No actions required
The technology/intervention	N/A	No comments received	No actions required
Population	N/A	No comments received	No actions required
Comparators	N/A	No comments received	No actions required
Outcomes	N/A	No comments received	No actions required
Economic analysis	N/A	No comments received	No actions required
Equality	N/A	No comments received	No actions required
Other considerations	N/A	No comments received	No actions required
Questions for consultation	N/A	No comments received	No actions required
Additional comments on the draft scope.	NCRI/RCP/RCR/ACP/JCCO	proposed appraisal is premature for scoping	Comment noted. It was agreed at the scoping workshop that early consideration of this topic would enable the Institute to issue timely guidance following marketing authorisation.
Comments on matrix of consultees & commentators	N/A	No comments received	No actions required

The following consultees/commentators indicated that they had no comments on the draft remit and/or the draft scope

1. Roche Products
2. NHS Quality Improvement Scotland
3. NPHS Wales
4. The Research Institute for the Care of Older People
5. Sanofi-aventis
6. Marie Curie Cancer Care
7. Royal Pharmaceutical Society